Medicine background
PT-141 / bremelanotide
A melanocortin-receptor agonist with a specific US licensed use.
Also discussed as: Vyleesi
THE RESEARCH QUESTION
What is being investigated?
The US medicine Vyleesi is indicated for acquired, generalised hypoactive sexual desire disorder in certain premenopausal women.
EVIDENCE SNAPSHOT
US approval for a specific indication
That indication does not establish it as a general libido, erectile-function or performance product. A research-labelled vial is not equivalent to the licensed medicine.
LIMITS & SAFETY
What should you know?
Nausea and blood-pressure effects are relevant. Uncontrolled hypertension and known cardiovascular disease are contraindications in the US label.
FOLLOW THE EVIDENCE
Sources & further reading
- DailyMed: VYLEESI (bremelanotide) prescribing information ↗US medicine label
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.